Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (28 ops.)
Latest filing published 12 Jun 2025 for Arcutis Biotherapeutics, Inc.. Read the official filing
Filing timeline
BuySaleTodd Franklin Watanabe
Insider track record
Disclosed buys
1
Disclosed sells
28
T+90 hit rate
100%
T+90 mean return
+18.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Todd Franklin Watanabe: trading record in brief
Todd Franklin Watanabe (chief executive) discloses dealings in Arcutis Biotherapeutics, Inc. to SEC (Form 4). Between 30 April 2021 and 10 June 2025, the trades on record add up to 53 filings.
Both buying and selling appear: 1 purchase worth €6,246, against 28 sales worth €1.9M. Sales outweigh purchases by €1.9M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 5 share grants and 15 option exercises. 2025 to date brings no purchases and 4 sales.
The latest filing, published on 12 June 2025, reports a transaction in Arcutis Biotherapeutics, Inc. The most recent open-market purchase was published on 3 December 2024, 684 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Todd Franklin Watanabe
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations53 total
997 shares0Common StockSEC:0002065881-25-000013:0
11,448 shares@ US$15.19197.4% of flowCommon StockSEC:0001787306-25-000085:0
1,500 shares@ US$17.52131.2% of flowCommon StockSEC:0001787306-25-000050:0
1,200 shares@ US$17.61420.9% of flowCommon StockSEC:0001787306-25-000048:0
151,000 shares0Common StockSEC:0001787306-25-000042:0
19,301 shares@ US$12.7011.5% of flowCommon StockSEC:0001787306-25-000016:0
15,000 shares@ US$15.171110.5% of flowCommon StockSEC:0001787306-24-000172:0
4,000 shares@ US$1.6920.3% of flowCommon StockSEC:0001787306-24-000166:0
Canonical exit: 29 Aug 2024 (T+90)
13,871 shares@ US$8.68425.3% of flowCommon StockSEC:0001787306-24-000144:0
14,487 shares@ US$9.01835.8% of flowCommon StockSEC:0001787306-24-000116:0
13,783 shares@ US$8.73785.4% of flowCommon StockSEC:0001787306-24-000070:0
14,903 shares@ US$11.12127.3% of flowCommon StockSEC:0001787306-24-000038:0
2,465 shares@ US$10.601.2% of flowCommon StockSEC:0001787306-24-000034:0
21,666 sharesCommon StockSEC:0001787306-24-000016:0
125,000 shares0Common StockSEC:0001787306-24-000006:0
6,563 shares0Common StockSEC:0001787306-23-000134:0
59,525 shares@ US$1.68064.4% of flowCommon StockSEC:0001787306-23-000129:0
87,500 shares0Common StockSEC:0001787306-23-000025:0
2,435 shares@ US$15.26381.7% of flowCommon StockSEC:0001567619-23-004672:0
2,343 shares@ US$16.16631.7% of flowCommon StockSEC:0001567619-23-004272:0
441 shares@ US$17.000.3% of flowCommon StockSEC:0001787306-23-000008:0
618 shares@ US$17.00440.5% of flowCommon StockSEC:0001787306-23-000006:0
1,000 shares@ US$17.060.8% of flowCommon StockSEC:0001787306-22-000079:0
1,000 shares@ US$18.0040.9% of flowCommon StockSEC:0001787306-22-000073:0
1,000 shares@ US$19.511.0% of flowCommon StockSEC:0001567619-22-018418:0
25 of 53 declarations
